Welcome to our dedicated page for ALLURION TECHNOLOGIES news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on ALLURION TECHNOLOGIES stock.
Allurion Technologies, Inc. develops a weight-loss platform centered on the Allurion Program, which combines the FDA PMA approved Allurion Gastric Balloon System featuring the Allurion Smart Capsule with a Virtual Care Suite that includes the Allurion Mobile App, Iris AI, Allurion Insights and the Allurion Connected Scale.
Company news centers on U.S. commercialization of the Allurion Smart Capsule, FDA regulatory status, provider training and commercial account onboarding, obesity-care partnerships and use of the program alongside GLP-1 therapies. Updates also cover preliminary operating results, balance-sheet and warrant-related capital actions, and listing-compliance matters involving Allurion common stock and warrants.
Allurion Technologies (NYSE: ALUR) has published a study in Clinical Obesity showcasing the effectiveness of the Allurion Program for weight loss and body composition improvement. The study, involving 167 patients with an average BMI of 31.3, demonstrated:
- 15.7% average weight reduction at 4 months
- 17.1% average weight loss at 6 months
- 14.7% average weight loss maintained at 12 months
Notably, patients experienced a significant decrease in body fat percentage from 39% to 35.7% at 6 months, while preserving muscle mass. The study reported no serious adverse events, highlighting the safety and efficacy of the Allurion Balloon in achieving sustainable weight loss and improved body composition.
Allurion Technologies (NYSE: ALUR) has announced the publication of a meta-analysis demonstrating the safety and effectiveness of the Allurion Program for weight loss. The systematic review, which analyzed 11 studies involving 2,107 patients conducted between 2016 and 2024, reported an average weight reduction of 12.5% and a significant BMI reduction of 4.75 kg/m2 at four months.
The analysis also confirmed the safety of the Allurion Balloon, with a low rate of serious adverse events at just 0.90%. Additionally, the study highlighted improvements in metabolic health parameters, including HDL cholesterol, triglycerides, and glycemia. Dr. Ram Chuttani, Chief Medical Officer and Founding Partner of Allurion, emphasized that these results further support the established safety and effectiveness of the Allurion Balloon, which has been documented in 26 peer-reviewed journal articles and used to treat over 150,000 patients worldwide.
Allurion Technologies (NYSE: ALUR), a company focused on ending obesity, has received a continued listing standards notice from the New York Stock Exchange (NYSE). The notice indicates that Allurion is not in compliance with NYSE's listing standards due to its average market capitalization falling below $50 million over a 30-day trading period ending August 29, 2024, and its last reported stockholders' equity being less than $50 million.
Allurion has 45 days to submit a plan to the NYSE outlining actions to regain compliance. If accepted, the company will have an 18-month cure period to meet the standards, during which its stock will continue to trade on the NYSE, subject to compliance with other listing requirements and periodic reviews.
Allurion Technologies (NYSE: ALUR) has published a study on the safety and effectiveness of the Allurion Program in adolescents with obesity. The study involved 91 adolescents aged 15-17 with an average BMI of 35.6. Key findings include:
- Average weight reduction of 13.1% four months after balloon placement
- No serious adverse events or early device removals
- Allurion Balloon offers a non-invasive treatment option for adolescent obesity
The study addresses growing concerns about adolescent obesity, which has quadrupled worldwide since 1990. The Allurion Balloon presents an alternative to invasive bariatric surgery and long-term pharmacotherapy, which raise concerns when applied to adolescents.
Allurion Technologies (NYSE: ALUR) has appointed Keith Johns to its Board of Directors, effective September 2, 2024. Johns brings over two decades of experience in the obesity management space, particularly with GLP-1 weight loss drugs. His expertise includes new product launches, reimbursement dynamics, and strategic partnerships.
Johns previously held senior leadership positions at Eli Lilly, most recently as head of Global Marketing and Alliance Management for the Diabetes and Obesity Business Unit. After retiring from Eli Lilly, he became COO at Adipo Therapeutics, focusing on brown adipose tissue for obesity treatment.
Allurion's leadership, including CEO Dr. Shantanu Gaur and Co-Chairman Omar Ishrak, expressed enthusiasm about Johns' appointment, citing his unique perspective on the rapidly growing obesity management market as a potential competitive advantage for the company.
Allurion Technologies (NYSE: ALUR) has published a study showing impressive weight loss results with its Allurion Program. 486 patients achieved an average weight reduction of 10.5% at four months, improving to 13.7% at one year. The program combines the Allurion Balloon with virtual guidance and support, including monthly assessments using the Allurion App, Connected Scale, and Health Tracker.
Patients had virtual access to registered dieticians, with weekly check-ups in the first month, biweekly for three months, and monthly for the remaining eight months. This approach contrasts with GLP-1 drugs, where patients typically regain about two-thirds of lost weight after discontinuing treatment and lifestyle intervention.
Allurion Technologies (NYSE: ALUR) has appointed Adrian Wild as Senior Vice President, International Commercial, effective August 13, 2024. Mr. Wild brings over 20 years of experience in building profitable commercial organizations at leading healthcare brands. He will lead Allurion's international commercial sales and operations functions as the company aims to advance toward profitability in the expanding obesity market.
Mr. Wild's extensive experience includes leadership roles at Align Technology, where he contributed to establishing a new standard of care and oversaw expansion in Europe. Most recently, he served as SVP and Head of Western Europe at Straumann Group, driving significant growth through strategic marketing and operational initiatives. Prior to that, he was VP, Commercial Excellence Global at Mölnlycke Health Care, improving commercial effectiveness across more than 100 countries.
Allurion Technologies (NYSE: ALUR) has received a notice from the New York Stock Exchange (NYSE) regarding non-compliance with continued listing standards. The company's average closing stock price fell below $1.00 over a 30-day trading period ending August 8, 2024. Allurion has a six-month cure period to regain compliance by achieving a closing share price and 30-day average closing price of at least $1.00.
The company intends to remain listed on the NYSE and is considering options to regain compliance, including a potential reverse stock split subject to stockholder approval. The notice does not result in immediate delisting, and Allurion's stock will continue to trade on the NYSE during the cure period, provided it meets other listing standards. This development is not expected to impact Allurion's ongoing business operations or SEC reporting requirements.
Allurion Technologies (NYSE: ALUR) reported Q2 2024 financial results, showing strong sequential revenue growth and record procedure volume. Key highlights include:
- Q2 revenue of $11.8 million, up 25% from Q1 2024
- Loss from operations reduced by 30% year-over-year
- Procedure volume grew 12% year-over-year, with over 10,000 balloon placements
- Updated 2024 revenue guidance to $40-$45 million
- Completed public offering raising $22 million in gross proceeds
The company faced a setback in France with the suspension of Allurion Balloon sales but is working on a remediation plan. Allurion aims to achieve profitability by the end of 2025 and continues to innovate, including expanding AI-powered weight loss coach capabilities.
Allurion Technologies, Inc. (NYSE: ALUR), a company focused on ending obesity, has announced that it will release its second quarter 2024 financial results on Tuesday, August 13, 2024. The company will host a conference call and live audio webcast on the same day at 8:30 AM ET to discuss the results and provide a business update.
Investors can access the conference call by dialing (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. The live audio webcast will be available on the Events section of Allurion's Investor Relations website. A replay of the call will be accessible by phone using Access Code 1905455, and the archived webcast will be available on the company's website.